These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 17219672)

  • 21. Occult hepatitis B in persons infected with HIV is associated with low CD4 counts and resolves during antiretroviral therapy.
    Cohen Stuart JW; Velema M; Schuurman R; Boucher CA; Hoepelman AI
    J Med Virol; 2009 Mar; 81(3):441-5. PubMed ID: 19152397
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CD4+ T-cell count increase in HIV-1-infected patients with suppressed viral load within 1 year after start of antiretroviral therapy.
    Wolbers M; Battegay M; Hirschel B; Furrer H; Cavassini M; Hasse B; Vernazza PL; Bernasconi E; Kaufmann G; Bucher HC;
    Antivir Ther; 2007; 12(6):889-97. PubMed ID: 17926643
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
    Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP; Yéni P;
    J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Residual viraemia in HIV-1-infected patients with plasma viral load Ostrowski SR; Katzenstein TL; Pedersen BK; Gerstoft J; Ullum H
    Scand J Immunol; 2008 Dec; 68(6):652-60. PubMed ID: 19055701
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The study to understand the natural history of HIV and AIDS in the era of effective therapy (SUN Study).
    Vellozzi C; Brooks JT; Bush TJ; Conley LJ; Henry K; Carpenter CC; Overton ET; Hammer J; Wood K; Holmberg SD;
    Am J Epidemiol; 2009 Mar; 169(5):642-52. PubMed ID: 19074775
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized clinical trial of community-based directly observed therapy as an adherence intervention for HAART among substance users.
    Macalino GE; Hogan JW; Mitty JA; Bazerman LB; Delong AK; Loewenthal H; Caliendo AM; Flanigan TP
    AIDS; 2007 Jul; 21(11):1473-7. PubMed ID: 17589194
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oral lesions as clinical markers of highly active antiretroviral therapy failure: a nested case-control study in Mexico City.
    Ramírez-Amador V; Ponce-de-León S; Anaya-Saavedra G; Crabtree Ramírez B; Sierra-Madero J
    Clin Infect Dis; 2007 Oct; 45(7):925-32. PubMed ID: 17806063
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of highly active antiretroviral therapy in HIV-1 infected children in Kenya.
    Song R; Jelagat J; Dzombo D; Mwalimu M; Mandaliya K; Shikely K; Essajee S
    Pediatrics; 2007 Oct; 120(4):e856-61. PubMed ID: 17846147
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibitory quotient as a prognostic factor of response to a salvage antiretroviral therapy containing ritonavir-boosted saquinavir. The CIVSA Study.
    Mallolas J; Blanco J; Labarga P; Vergara A; Ocampo A; Sarasa M; Arnedo M; López-Púa Y; García J; Juega J; Guelar A; Terrón A; Dalmau D; García I; Zárraga M; Martínez E; Carné X; Pumarola T; Escayola R; Gatell J
    HIV Med; 2007 May; 8(4):226-33. PubMed ID: 17461850
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oral lesions as predictors of highly active antiretroviral therapy failure in Brazilian HIV-infected children.
    Miziara ID; Weber R
    J Oral Pathol Med; 2008 Feb; 37(2):99-106. PubMed ID: 18197855
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predicting the evolution of Kaposi sarcoma, in the highly active antiretroviral therapy era.
    El Amari EB; Toutous-Trellu L; Gayet-Ageron A; Baumann M; Cathomas G; Steffen I; Erb P; Mueller NJ; Furrer H; Cavassini M; Vernazza P; Hirsch HH; Bernasconi E; Hirschel B;
    AIDS; 2008 May; 22(9):1019-28. PubMed ID: 18520345
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of ocular manifestations and blindness in HIV/AIDS patients on HAART in a tertiary care hospital in western India.
    Shah SU; Kerkar SP; Pazare AR
    Br J Ophthalmol; 2009 Jan; 93(1):88-90. PubMed ID: 18952644
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stable recovery from HCV in HIV-HCV co-infection under antiretroviral therapy.
    Zeitoun JD; Mallet V; Chaix ML; Viard JP; Blanche S; Pol S
    J Clin Virol; 2007 Sep; 40(1):71-3. PubMed ID: 17658294
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [CD4+ guided interruption HAART in HIV patients].
    Antolini D; Lanzafame M; Lattuada E; Vento S; Concia E
    Recenti Prog Med; 2007 Oct; 98(10):501-5. PubMed ID: 17970175
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment initiation with zidovudine-containing potent antiretroviral therapy impairs CD4 cell count recovery but not clinical efficacy.
    Huttner AC; Kaufmann GR; Battegay M; Weber R; Opravil M
    AIDS; 2007 May; 21(8):939-46. PubMed ID: 17457087
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Herbs for HIV infection.
    Maeda Y; Naiki Y; Matsuo K; Miyatake J; Suakaguchi M; Matsuda M; Kanamaru A
    Am J Hematol; 2002 Jul; 70(3):263-4. PubMed ID: 12111775
    [No Abstract]   [Full Text] [Related]  

  • 37. Changes in HIV-related hospitalizations during the HAART era in an inner-city hospital.
    Pulvirenti J; Muppidi U; Glowacki R; Cristofano M; Baker L
    AIDS Read; 2007 Aug; 17(8):390-4, 397-401. PubMed ID: 17717882
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HIV-1 DNA load analysis in peripheral blood lymphocytes and monocytes from naïve and HAART-treated individuals.
    Gibellini D; Borderi M; De Crignis E; Cicola R; Cimatti L; Vitone F; Chiodo F; Re MC
    J Infect; 2008 Mar; 56(3):219-25. PubMed ID: 18276011
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunovirological and therapeutic follow-up of HIV-1/HIV-2-dually seropositive patients.
    Landman R; Damond F; Gerbe J; Brun-Vezinet F; Yeni P; Matheron S
    AIDS; 2009 Jan; 23(3):426-8. PubMed ID: 19114866
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Side effects and complications. Tesamorelin--results from Phase III.
    TreatmentUpdate; 2007; 19(3):6-7. PubMed ID: 17575575
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.